BACKGROUND: Mepolizumab (MPZ), an anti-interleukin-5 antibody, is effective for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). However, its effectiveness has not been adequately evaluated in real-world clinical practice. In this study, we assessed the effectiveness and safety of MPZ (300 mg) for relapsing/refractory EGPA resistant to corticosteroids (CS) for 1 year in real-world settings. METHODS: We administered MPZ (300 mg) to 16 patients with relapsing/refractory EGPA resistant to CS (Post-MPZ). We also retrospectively collected data from the same patients for the 12 months before the administration of MPZ (Pre-MPZ). The primary endpoint was the 12-month remission rate after MPZ administration and the secondary endpoints were the Birmingham vasculitis activity score (BVAS), vasculitis damage index (VDI), eosinophil counts, changes in concomitant CS doses/concomitant immunosuppressant use, MPZ retention rate, and incidence of adverse events. The clinical course was compared between Pre-MPZ and Post-MPZ. RESULTS: The 12-month remission rate after the initiation of MPZ was 75%. No change was observed in BVAS, eosinophil count, or concomitant CS dose over time in the Pre-MPZ group, whereas all these parameters were significantly decreased over time in the Post-MPZ group. The number of patients using concomitant immunosuppressant also decreased over time in the Post-MPZ group. VDI did not increase in either group. The MPZ retention rate was 100% and only three patients (18.8%) had infections. Changes in BVAS, eosinophil count, and cumulative concomitant CS dose were significantly lower in the Post-MPZ group than in the Pre-MPZ group. There was no significant difference in the changes in VDI between the groups. CONCLUSION: This study demonstrated that MPZ is effective and safe for EGPA. Furthermore, MPZ decreases disease activity, increases remission rate, and has a CS-sparing effect.
BACKGROUND:Mepolizumab (MPZ), an anti-interleukin-5 antibody, is effective for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). However, its effectiveness has not been adequately evaluated in real-world clinical practice. In this study, we assessed the effectiveness and safety of MPZ (300 mg) for relapsing/refractory EGPA resistant to corticosteroids (CS) for 1 year in real-world settings. METHODS: We administered MPZ (300 mg) to 16 patients with relapsing/refractory EGPA resistant to CS (Post-MPZ). We also retrospectively collected data from the same patients for the 12 months before the administration of MPZ (Pre-MPZ). The primary endpoint was the 12-month remission rate after MPZ administration and the secondary endpoints were the Birmingham vasculitis activity score (BVAS), vasculitis damage index (VDI), eosinophil counts, changes in concomitant CS doses/concomitant immunosuppressant use, MPZ retention rate, and incidence of adverse events. The clinical course was compared between Pre-MPZ and Post-MPZ. RESULTS: The 12-month remission rate after the initiation of MPZ was 75%. No change was observed in BVAS, eosinophil count, or concomitant CS dose over time in the Pre-MPZ group, whereas all these parameters were significantly decreased over time in the Post-MPZ group. The number of patients using concomitant immunosuppressant also decreased over time in the Post-MPZ group. VDI did not increase in either group. The MPZ retention rate was 100% and only three patients (18.8%) had infections. Changes in BVAS, eosinophil count, and cumulative concomitant CS dose were significantly lower in the Post-MPZ group than in the Pre-MPZ group. There was no significant difference in the changes in VDI between the groups. CONCLUSION: This study demonstrated that MPZ is effective and safe for EGPA. Furthermore, MPZ decreases disease activity, increases remission rate, and has a CS-sparing effect.
Entities:
Keywords:
Corticosteroid; Eosinophilic granulomatosis with polyangiitis; Mepolizumab; Treatment
Authors: Cécile-Audrey Durel; Julien Berthiller; Silvia Caboni; David Jayne; Jacques Ninet; Arnaud Hot Journal: Arthritis Care Res (Hoboken) Date: 2016-03 Impact factor: 4.794
Authors: Oliver Flossmann; Paul Bacon; Kirsten de Groot; David Jayne; Niels Rasmussen; Philip Seo; Kerstin Westman; Raashid Luqmani Journal: Ann Rheum Dis Date: 2006-05-25 Impact factor: 19.103
Authors: A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt Journal: Arthritis Rheum Date: 1990-08
Authors: Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich Journal: N Engl J Med Date: 2017-05-18 Impact factor: 91.245
Authors: C Mukhtyar; R Lee; D Brown; D Carruthers; B Dasgupta; S Dubey; O Flossmann; C Hall; J Hollywood; D Jayne; R Jones; P Lanyon; A Muir; D Scott; L Young; R A Luqmani Journal: Ann Rheum Dis Date: 2008-12-03 Impact factor: 19.103
Authors: Xavier Puéchal; Christian Pagnoux; Gabriel Baron; Thomas Quémeneur; Antoine Néel; Christian Agard; François Lifermann; Eric Liozon; Marc Ruivard; Pascal Godmer; Nicolas Limal; Arsène Mékinian; Thomas Papo; Anne-Marie Ruppert; Anne Bourgarit; Boris Bienvenu; Loïck Geffray; Jean-Luc Saraux; Elisabeth Diot; Bruno Crestani; Xavier Delbrel; Laurent Sailler; Pascal Cohen; Véronique Le Guern; Benjamin Terrier; Matthieu Groh; Claire Le Jeunne; Luc Mouthon; Philippe Ravaud; Loïc Guillevin Journal: Arthritis Rheumatol Date: 2017-10-15 Impact factor: 10.995
Authors: J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts Journal: Arthritis Rheum Date: 2013-01
Authors: M Yates; R A Watts; I M Bajema; M C Cid; B Crestani; T Hauser; B Hellmich; J U Holle; M Laudien; M A Little; R A Luqmani; A Mahr; P A Merkel; J Mills; J Mooney; M Segelmark; V Tesar; K Westman; A Vaglio; N Yalçındağ; D R Jayne; C Mukhtyar Journal: Ann Rheum Dis Date: 2016-06-23 Impact factor: 27.973